Background/Aims Tenofovir alafenamide (TAF) has shown less favorable effect on lipids
compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding …

Background The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and
other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B …

Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering
effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect …

BACKGROUND Tenofovir alafenamide (TAF) has a serum lipid-raising effect in patients with
HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in …

Abstract Background and Aims We used real‐world data to evaluate the efficacy and safety
of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in …

Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line
treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in …

For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-
disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and …

Background Lipid‐lowering effect was observed during treatment with tenofovir disoproxil
fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients …

Abstract Background and Aim Tenofovir alafenamide (TAF) is a new prodrug of tenofovir,
enabling treatment of patients with hepatitis B virus (HBV) infection at a lower dose than …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …